Opioid Brain Injury
Chronic musculoskeletal pain — persistent low back pain, osteoarthritis, widespread myofascial pain — is among the most common and most consequential conditions I treat. For decades, opioids were a default component of the management strategy for these patients, normalized by prescribing culture, patient expectation, and a genuine lack of alternatives that were being offered consistently. That era is ending, and not because of regulatory pressure alone — but because the evidence has become impossible to rationalize away. Opioids do not work well for chronic musculoskeletal pain, and the harms they produce are serious, progressive, and in some cases permanent.
THE BASICS
Why Opioids Are Not the Answer for Chronic Musculoskeletal Pain
Opioids were developed for acute pain, cancer pain, and end-of-life comfort — contexts where short-term analgesia is the primary goal and long-term biological consequences are secondary considerations. Chronic non-cancer musculoskeletal pain is a fundamentally different problem, and the evidence that opioids address it effectively is remarkably thin. Studies consistently show only modest improvements in pain and function with opioid therapy, improvements that are frequently outweighed by side effects and that do not persist over time. After months or years of use, patients on long-term opioid therapy often report no greater pain relief than patients managed with non-opioid alternatives — while carrying a substantially higher burden of adverse effects, dependence, and physiological harm. Tolerance develops with chronic use, requiring dose escalation that increases risk without producing proportional benefit. The 2022 CDC Guidelines for Prescribing Opioids for Chronic Pain state plainly that there is no evidence opioids improve pain or function with long-term use in chronic musculoskeletal conditions. That is not a fringe position — it is the current consensus of the leading public health and clinical authorities in this space.
CLINICAL EVIDENCE
Two Mechanisms of Harm That Deserve More Attention
Beyond the well-publicized risks of dependence, overdose, and hormonal dysregulation, two specific biological consequences of chronic opioid use are insufficiently discussed with patients and deserve direct attention in the clinical conversation.
The first is structural brain injury. Neuroimaging studies have documented gray matter atrophy in the prefrontal cortex — the region governing decision-making, impulse control, and executive function — as well as volume reduction in the amygdala and anterior cingulate cortex, areas central to pain modulation and emotional regulation. These changes have been observed even in younger users and correlate with duration of exposure and cumulative dose. Some of these alterations appear to be partially irreversible. I have described this constellation of neurological damage as Opioid Brain Injury — a term intended to capture what is medically characterized as toxic leukoencephalopathy resulting from opioid exposure, encompassing the white matter injury and structural changes that chronic opioid use produces in the central nervous system. Upadhyay et al. in the Journal of Neuroscience documented these alterations directly in prescription opioid-dependent patients, finding persistent and potentially irreversible changes in brain structure and functional connectivity. The clinical consequences — cognitive dysfunction, mood disorders, and elevated risk of substance misuse — compound the original pain problem rather than resolving it.
The second is opioid-induced hyperalgesia, a paradoxical and clinically important phenomenon in which long-term opioid use produces increased sensitivity to pain rather than decreased sensitivity. The nervous system becomes amplified in its response to normal pain signals, patients report worsening pain even as doses are raised, and the pain itself becomes diffuse, poorly localized, and increasingly difficult to manage through any mechanism. The biological substrate involves excitation of NMDA receptors, increased spinal dynorphin expression, and disruption of descending pain inhibitory pathways. The clinical result is a vicious cycle in which more opioids produce more pain, which drives demand for more opioids — a cycle that is difficult to interrupt and that leaves patients in a worse functional state than they would have been without opioid therapy. Lee et al. in Pain Physician characterized opioid-induced hyperalgesia as a recognized and serious clinical phenomenon that may worsen pain with prolonged opioid therapy — and that recognition should be a standard part of the informed consent conversation before any patient is started on long-term opioid management.
The additional risks — physical dependence and addiction even at therapeutic doses, overdose mortality, suppression of sex hormones with long-term use, sedation-related falls and fractures particularly in older adults, and the well-known gastrointestinal effects — represent a harm profile that in the chronic musculoskeletal pain context is rarely justified by the modest and transient benefit opioids typically produce.
PATIENT SELECTION
What Works Instead
The alternatives to opioid therapy for chronic musculoskeletal pain are not consolation prizes — they are, for most patients, more effective and more durable. Structured physical therapy and progressive exercise produce improvements in pain and function that are comparable to or superior to opioid therapy for most chronic musculoskeletal conditions, without the adverse effect profile and with benefits that compound over time rather than diminishing. Cognitive behavioral therapy addresses the central sensitization and psychological amplification that contribute substantially to the chronic pain experience and that pharmacological management alone cannot reach. Non-opioid pharmacological options including NSAIDs, duloxetine, and gabapentinoids offer meaningful relief for specific pain phenotypes with substantially lower risk profiles. Osteopathic manipulative medicine provides hands-on tools for addressing musculoskeletal dysfunction and improving mobility in patients for whom manual therapy is appropriate. Interventional procedures — nerve blocks, image-guided injections, radiofrequency ablation, and minimally invasive spine interventions — address confirmed pain generators directly and can produce durable relief that eliminates or substantially reduces the analgesic requirement. Regenerative medicine with PRP and BMAC offers the possibility of tissue-level improvement for tendon, joint, and disc pathology that is driving the pain rather than masking it.
The key in all of these approaches is what is missing from opioid prescribing as it has typically been practiced: a confirmed diagnosis, a treatment matched to that diagnosis, and a plan built around function rather than symptom suppression.
FOR REFERRING CLINICIANS
Patients on long-term opioid therapy for chronic musculoskeletal pain who have not had a comprehensive interventional spine or musculoskeletal evaluation represent one of the most important referral opportunities in pain medicine. Many of these patients have a treatable pain generator that has never been identified — and identifying it changes what is possible for their management. I offer comprehensive diagnostic evaluation including targeted image-guided diagnostic blocks to confirm pain sources, a full range of interventional procedures matched to confirmed diagnoses, non-opioid pharmacological optimization, and coordination of physical therapy and cognitive behavioral therapy as components of a comprehensive management plan. For patients seeking to reduce or discontinue opioid therapy, a structured transition plan built around confirmed diagnosis and matched non-opioid treatment is the most reliable pathway to success. I welcome direct physician-to-physician consultation.
PERSPECTIVE
A Note on Honest Conversations About Opioids
One of the most important things I can do for a patient on long-term opioid therapy for musculoskeletal pain is to tell them the truth — that the medication they have been taking for years is unlikely to be providing meaningful benefit at this stage, that the harms it carries are real and progressive, and that there are alternatives worth pursuing that have never been adequately offered to them. That conversation is not always comfortable, and it requires time, care, and a genuine relationship of trust. But it is the conversation that changes trajectories. The chronic pain epidemic in this country was not created by patient weakness or physician malice — it was created by a system that reached for the most available tool without asking whether it was the right one. Correcting that requires physicians who are willing to do the harder diagnostic work, offer the more precise interventional options, and have the honest conversation about what opioids do and do not accomplish in the long run. That is the standard I hold myself to, and it is what every patient living with chronic musculoskeletal pain deserves.
DISCLOSURE & REFERENCES
This article is for educational purposes and reflects clinical experience and interpretation of published literature. It is not a substitute for individualized medical evaluation. Key references: Upadhyay J et al. 2010 (brain alterations in opioid dependence, J Neurosci); Lee M et al. 2011 (opioid-induced hyperalgesia, Pain Physician); Chou R et al. 2015 (long-term opioid therapy risks, Ann Intern Med); Vowles KE et al. 2015 (opioid misuse rates in chronic pain, Pain); Dowell D et al. 2022 (CDC opioid prescribing guidelines, MMWR).
ABOUT THE AUTHOR
Dr. Mahajer is a double board-certified physiatrist and sports medicine physician, fellowship-trained in Interventional Spine & Sports Medicine at the Icahn School of Medicine at Mount Sinai. He is an Assistant Professor of Neuroscience at FIU Herbert Wertheim College of Medicine. He is the Immediate Past President of the American Osteopathic College of Physical Medicine and Rehabilitation (AOCPMR), holds medical licenses in Florida, New York, and California, and has been recognized as a Top Physiatrist and Top Doctor in both Florida and New York.
